LEGEND-T2DM Evidence Dissemination Summary

Target: **saxagliptin**, Comparator: **glimepiride** Outcome: **Acute pancreatitis** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	10,353	8,104	16	1.97
Clinformatics	9,438	8,388	20	2.38
DA Germany	1,053	1,255	0	0.00
LDP France	-	-	-	-
MDCD	-	-	-	-
MDCR	1,729	1,658	<5	<3.02
Open Claims	48,821	38,498	95	2.47
Optum EHR	6,032	2,171	<5	<2.30
Veterans Affairs	10,714	9,776	27	2.76

How Reliable Are the Effect Estimates? (Objective diagnostics)

Legend: Comparator — Target — Before — After — MDRR — Negative control — Calibrated estimate

Data source	Equipoise	Max ASDM	MDRR	EASE	Hazard ratio (Calibrated estimate)
CCAE	Equipoise = 0.44	Max ASDM = 0.06	MDRR = 2.0	EASE = 0.04	0.41 (0.18 – 0.96)
Clinformatics	Equipoise = 0.50	Max ASDM = 0.05	MDRR = 1.7	EASE = 0.07	1.17 (0.62 – 2.19)
DA Germany	Equipoise = 0.73	Max ASDM = 0.12	MDRR = Inf	EASE = 0.07	
LDP France					
MDCD					
MDCR	Equipoise = 0.61	Max ASDM = 0.16	MDRR = 3.7	EASE = 0.05	0.71 (0.14 – 3.53)
Open Claims	Equipoise = 0.48	Max ASDM = 0.03	MDRR = 1.3	EASE = 0.02	1.21 (0.94 – 1.54)
Optum EHR	Equipoise = 0.45	Max ASDM = 0.11	MDRR = 2.6	EASE = 0.06	0.49 (0.10 – 2.30)
Veterans Affairs	Equipoise = 0.20	Max ASDM = 0.20	MDRR = 3.4	EASE = 0.07	1.96 (0.18 – 21.66)

Axis labels: Preference score | Std. diff. means | MDRR | Hazard ratio | Hazard ratio

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

Legend: MDRR — Negative control — Estimate — Calibrated estimate

	MDRR	EASE	I²	Hazard ratio (Calibrated estimate)
Meta-analysis	MDRR = 1.9	EASE = 0.03	$I^2 = 0.61$	0.85 (0.48 – 1.52)

Axis labels: MDRR | Hazard ratio | Hazard ratio | Hazard ratio